Open an account

Novavax

NVAX · NASDAQ

$11.43+$0.61 (+5.64%)TodayMarket closed ·
Prev close $10.82

About NVAX

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company is headquartered in Gaithersburg, Maryland and currently employs 749 full-time employees. The company is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. The company provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.

Employees
749
Headquarters
Gaithersburg, Maryland
Listed
May 16, 1973
Sector
Health Care
Industry
Biotechnology
Website
novavax.com

NVAX key statistics

Market cap
1.89B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
8.70M
Volume
5.46M
Open price
$10.75
High today
$11.57
Low today
$10.55
52 Week high
$13.39
52 Week low
$6.20

Novavax (NVAX) at a glance

Novavax (NVAX) last traded at $11.43, with a market cap of 1.89B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $10.55 and $11.57. The current price is 8.3% above the day's low and 1.2% below its high.

Volume so far is 5.46M shares, below the average of 8.70M shares a day.

Over the past year Novavax has ranged from $6.20 to $13.39, and now sits 73% of the way up that range.

Novavax met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.32 per share against an estimate of -$0.3933.

The average analyst price target is $14.28, 24.9% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 8 analyst ratings say Buy
  • Buy50.0%
  • Hold25.0%
  • Sell25.0%
Price target · 11 analystsAvg $14.28
Low
$7.07
Now
$11.43
High
$26.25

NVAX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 226.0% on average.

  1. Q3 FY24: reported -$0.76 per share against an estimate of -$0.8078
  2. Q4 FY24: reported -$0.83 per share against an estimate of -$0.5243
  3. Q1 FY25: reported $2.93 per share against an estimate of $0.7201
  4. Q2 FY25: reported $0.62 per share against an estimate of -$0.0852
  5. Q3 FY25: reported -$1.25 per share against an estimate of -$1.21
  6. Q4 FY25: reported $0.11 per share against an estimate of -$0.4967
  7. Q1 FY26: reported -$0.06 per share against an estimate of -$0.2349
  8. Q2 FY26: reported -$0.32 per share against an estimate of -$0.3933

NVAX news

  • Vandana Singh

    Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push

  • Ananya Gairola

    Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'

  • Neeraj Jain

    A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally

  • Avi Kapoor

    Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday

  • 'Russia Denies Report of Second Case of Illness in Siberia' - Bloomberg

  • Transcript: Novavax Q2 2026 Earnings Conference Call

  • Evette Mitkov

    Novavax Stock Falls Back: What's Going On?

  • Mohd Haider

    Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety

Similar companies

Companies in the same industry as Novavax

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.